155 related articles for article (PubMed ID: 32197218)
21. The NAB2-STAT6 gene fusion in solitary fibrous tumor can be reliably detected by anchored multiplexed PCR for targeted next-generation sequencing.
Guseva NV; Tanas MR; Stence AA; Sompallae R; Schade JC; Bossler AD; Bellizzi AM; Ma D
Cancer Genet; 2016; 209(7-8):303-12. PubMed ID: 27292373
[TBL] [Abstract][Full Text] [Related]
22. Clinical Evaluation of Massively Parallel RNA Sequencing for Detecting Recurrent Gene Fusions in Hematologic Malignancies.
Kim B; Lee H; Shin S; Lee ST; Choi JR
J Mol Diagn; 2019 Jan; 21(1):163-170. PubMed ID: 30347268
[TBL] [Abstract][Full Text] [Related]
23. Clinical Validation of FusionPlex RNA Sequencing and Its Utility in the Diagnosis and Classification of Hematologic Neoplasms.
Chen X; Wang W; Yeh J; Wu Y; Oehler VG; Naresh KN; Liu YJ
J Mol Diagn; 2023 Dec; 25(12):932-944. PubMed ID: 37813298
[TBL] [Abstract][Full Text] [Related]
24. Detection of TMPRSS2-ETS fusions by a multiprobe fluorescence in situ hybridization assay for the early diagnosis of prostate cancer: a pilot study.
Sun QP; Li LY; Chen Z; Pang J; Yang WJ; Zhou XF; Qiu JG; Su ZL; He D; Gao X
J Mol Diagn; 2010 Sep; 12(5):718-24. PubMed ID: 20616363
[TBL] [Abstract][Full Text] [Related]
25. Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing.
Pflueger D; Terry S; Sboner A; Habegger L; Esgueva R; Lin PC; Svensson MA; Kitabayashi N; Moss BJ; MacDonald TY; Cao X; Barrette T; Tewari AK; Chee MS; Chinnaiyan AM; Rickman DS; Demichelis F; Gerstein MB; Rubin MA
Genome Res; 2011 Jan; 21(1):56-67. PubMed ID: 21036922
[TBL] [Abstract][Full Text] [Related]
26. Weak-evidence Fusion Candidates Detected by a FusionPlex Assay Using the Ion Torrent System.
Fujita S; Masago K; Sasaki E; Tsukushi S; Horio Y; Kuroda H; Hida T
In Vivo; 2021; 35(2):993-998. PubMed ID: 33622894
[TBL] [Abstract][Full Text] [Related]
27. Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models.
Linn DE; Bronson RT; Li Z
PLoS One; 2015; 10(3):e0120628. PubMed ID: 25780911
[TBL] [Abstract][Full Text] [Related]
28. Human phosphodiesterase 4D7 (PDE4D7) expression is increased in TMPRSS2-ERG-positive primary prostate cancer and independently adds to a reduced risk of post-surgical disease progression.
Böttcher R; Henderson DJ; Dulla K; van Strijp D; Waanders LF; Tevz G; Lehman ML; Merkle D; van Leenders GJ; Baillie GS; Jenster G; Houslay MD; Hoffmann R
Br J Cancer; 2015 Nov; 113(10):1502-11. PubMed ID: 26575822
[TBL] [Abstract][Full Text] [Related]
29. Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches.
Vendrell JA; Taviaux S; Béganton B; Godreuil S; Audran P; Grand D; Clermont E; Serre I; Szablewski V; Coopman P; Mazières J; Costes V; Pujol JL; Brousset P; Rouquette I; Solassol J
Sci Rep; 2017 Oct; 7(1):12510. PubMed ID: 28970558
[TBL] [Abstract][Full Text] [Related]
30. Comparison of Homologous Recombination Repair Gene Next-Generation Sequencing Analysis in Patients With Metastatic Castration-Resistant Prostate Cancer Between Local and Central Laboratories in Korea.
Kim Y; Park I; Kim B; Choi YJ; Oh SC; Lee KA
Ann Lab Med; 2023 Jan; 43(1):64-72. PubMed ID: 36045058
[TBL] [Abstract][Full Text] [Related]
31. TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer.
Reig Ò; Marín-Aguilera M; Carrera G; Jiménez N; Paré L; García-Recio S; Gaba L; Pereira MV; Fernández P; Prat A; Mellado B
Eur Urol; 2016 Nov; 70(5):709-713. PubMed ID: 26948395
[TBL] [Abstract][Full Text] [Related]
32. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer.
Perner S; Demichelis F; Beroukhim R; Schmidt FH; Mosquera JM; Setlur S; Tchinda J; Tomlins SA; Hofer MD; Pienta KG; Kuefer R; Vessella R; Sun XW; Meyerson M; Lee C; Sellers WR; Chinnaiyan AM; Rubin MA
Cancer Res; 2006 Sep; 66(17):8337-41. PubMed ID: 16951139
[TBL] [Abstract][Full Text] [Related]
33. Retention of Interstitial Genes between
Murphy SJ; Kosari F; Karnes RJ; Nasir A; Johnson SH; Gaitatzes AG; Smadbeck JB; Rangel LJ; Vasmatzis G; Cheville JC
Cancer Res; 2017 Nov; 77(22):6157-6167. PubMed ID: 29127096
[No Abstract] [Full Text] [Related]
34. Intergenic Breakpoints Identified by DNA Sequencing Confound Targetable Kinase Fusion Detection in NSCLC.
Li W; Liu Y; Li W; Chen L; Ying J
J Thorac Oncol; 2020 Jul; 15(7):1223-1231. PubMed ID: 32151779
[TBL] [Abstract][Full Text] [Related]
35. Novel exon-exon breakpoint in
Loke BN; Lee VKM; Sudhanshi J; Wong MK; Kuick CH; Puhaindran M; Chang KTE
J Clin Pathol; 2017 Aug; 70(8):697-701. PubMed ID: 28137728
[TBL] [Abstract][Full Text] [Related]
36. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.
Mehra R; Tomlins SA; Yu J; Cao X; Wang L; Menon A; Rubin MA; Pienta KJ; Shah RB; Chinnaiyan AM
Cancer Res; 2008 May; 68(10):3584-90. PubMed ID: 18483239
[TBL] [Abstract][Full Text] [Related]
37. Identification and characterization of novel fusion genes in prostate cancer by targeted RNA capture and next-generation sequencing.
Yang J; Chen Y; Lu J; Wang X; Wang L; Liang J; Sun ZS
Acta Biochim Biophys Sin (Shanghai); 2018 Nov; 50(11):1166-1172. PubMed ID: 30307468
[TBL] [Abstract][Full Text] [Related]
38. ETS fusion genes in prostate cancer.
Gasi Tandefelt D; Boormans J; Hermans K; Trapman J
Endocr Relat Cancer; 2014 Jun; 21(3):R143-52. PubMed ID: 24659477
[TBL] [Abstract][Full Text] [Related]
39. Feasibility and clinical utility of a pan-solid tumor targeted RNA fusion panel: A single center experience.
Hindi I; Shen G; Tan Q; Cotzia P; Snuderl M; Feng X; Jour G
Exp Mol Pathol; 2020 Jun; 114():104403. PubMed ID: 32061944
[TBL] [Abstract][Full Text] [Related]
40. Antibody-independent targeted quantification of TMPRSS2-ERG fusion protein products in prostate cancer.
He J; Sun X; Shi T; Schepmoes AA; Fillmore TL; Petyuk VA; Xie F; Zhao R; Gritsenko MA; Yang F; Kitabayashi N; Chae SS; Rubin MA; Siddiqui J; Wei JT; Chinnaiyan AM; Qian WJ; Smith RD; Kagan J; Srivastava S; Rodland KD; Liu T; Camp DG
Mol Oncol; 2014 Oct; 8(7):1169-80. PubMed ID: 25266362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]